Company Overview
About Cellanome
Cellanome is a biotechnology tools company founded in 2021 and headquartered in Menlo Park, California. The company is developing a next-generation multi-omics platform designed to simultaneously measure multiple layers of biological information — including genomics, transcriptomics, and proteomics — at single-cell resolution and at unprecedented scale. Its platform integrates genome sequencing, microfluidics, and proprietary integrated sensors to capture a more complete molecular portrait of individual cells than any existing single-omics technology can achieve alone.
Business Model & Competitive Advantage
Cellanome raised a $100M Series A in 2023 co-led by GV (Google Ventures) and Andreessen Horowitz (a16z Bio), with participation from Meritech Capital and others — a rare nine-figure Series A that signals exceptional investor conviction in the platform's potential. The company's technology is aimed at transforming how researchers understand complex biological systems, with applications in drug discovery (identifying new drug targets by characterizing disease cell populations), diagnostics (detecting disease-associated cellular changes at high resolution), and fundamental cell biology research.
Competitive Landscape 2025–2026
The single-cell multi-omics tools market is growing rapidly, driven by demand from pharmaceutical companies, academic research institutions, and biotech drug developers. Cellanome competes with established genomics tools companies — principally 10x Genomics (which dominates single-cell transcriptomics) — as well as emerging multi-omics platforms from companies like Parse Biosciences and Scale Bio. Cellanome's differentiation lies in the integration of multiple measurement modalities (not just gene expression but also protein and epigenetic layers) within a single cell, at scale, which has been the frontier challenge in the field.
Key Differentiators
Emerging Innovator
Cellanome is an emerging player bringing innovative solutions to the Life Sciences & BioTech market.
Frequently Asked Questions
Estimated Visibility Trend (Beta)
Simulated 8-week rolling score
Based on estimated brand signals. Historical tracking coming soon.
Similar Brands
Emulate
Emulate, Inc. is a Boston-based biotechnology company that designs, manufactures, and commercializes Organ-Chip technology — micro-engineered devices lined with living human cells that replicate the m
Neuralink
Neuralink is a neurotechnology company founded in 2016 by Elon Musk and a team of neuroscientists and engineers, developing implantable brain-computer interface devices that enable individuals with pa
Tempus
Tempus AI is a technology company applying artificial intelligence to advance precision medicine across oncology, neurology, psychiatry, and cardiology. Founded in 2015 by Eric Lefkofsky (co-founder o
ConcertAI
ConcertAI is a Boston-based company that combines artificial intelligence with real-world oncology data to accelerate cancer drug development and improve patient outcomes. Its platform integrates mult
DNAnexus
DNAnexus is the category-defining cloud platform for precision health data management, analysis, and collaboration. Founded in 2009 and headquartered in Mountain View, California, DNAnexus provides a
Saluda Medical
Saluda Medical is a commercial-stage medical device company that has pioneered closed-loop neuromodulation therapy for chronic pain management. Headquartered in Macquarie Park, Australia (with US oper
Compare Cellanome with Competitors
Side-by-side AI visibility scores, platform breakdown, and market position.
Claim This Profile
Are you from Cellanome? Claim your profile to see full AI mention excerpts, get weekly visibility change alerts, and optimize how AI systems describe your brand.
Claim Cellanome Profile →Track AI Visibility in Real Time
Monitor how ChatGPT, Gemini, Perplexity, and Claude mention Cellanome vs competitors. Get alerts when AI recommendations shift.
Start Free Tracking →